Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Reuters NewMedia - Wednesday, October 4, 2000
Gene Emery

The study, funded by the drug's maker Glaxo Wellcome (GLXO.L) (NYSE:GLX - news), was designed to find out if lower and less expensive dosages of AZT might reduce the number of AIDS babies in developing countries.

The research is expected to have little effect on medical care in developed countries, where combination drug therapies have replaced AZT-only treatment for AIDS.

Sales of AZT have dropped significantly since the adoption of such therapies in the West, said PaineWebber analyst Jeff Chaffkin, who follows Glaxo Wellcome Plc.

"Although there is still a need for AZT in developing countries, they don't have the resources to pay for it," Chaffkin said.

In tests where some mothers and newborns received scaled-back therapy, Dr. Marc Lallemant and his colleagues found the shortened drug regimen for both the pregnant mother and her newborn doubled the risk that a baby would be born with the AIDS virus, compared to volunteers and their babies who received the full treatment.

They also found that only 1.6 percent of the women who got the full dose of AZT beginning at the 28th week of pregnancy had babies infected with the AIDS virus, compared with a rate of 5.1 percent when the mother's AZT therapy began in the 35th week.

But if the mother was unable to get the full 11-week treatment before giving birth, it was better to give a full six-week dose of AZT to the newborn, instead of just three days of AZT therapy, the Lallemant team concluded.

In an editorial, doctors Catherine Peckham and Marie-Louise Newell of the Institute of Child Health in London said doctors in developing countries not only lacked the resources to treat infected women, but "there is the additional challenge of preventing transmission (of the AIDS virus) through breast-feeding without jeopardizing the health of the child."

The study's design drew praise from Public Citizen, a U.S. consumer health group that has criticized the use of placebo pills in previous attempts to find less-expensive ways to prevent the spread of AIDS in developing countries.

Public Citizen and others have characterized the practice as unethical.

Doctors involved in those studies have defended the work by oting that their volunteers would not have received AZT reatment anyway.

"Unlike more than a dozen other studies that provided at least some pregnant women with either placebos or treatments not proven to be effective, this study provided AZT to all pregnant women," said Dr. Peter Lurie, deputy director of Public Citizen's Health Research Group. "It shows you can have the best ethics and the best science."

001004
RE001004

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .